Search

Date 2015 Author/Creator Voit, Thomas

1. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy. Issue 1 (December 2015)

Authors:
Pinto-Mariz, Fernanda; Rodrigues Carvalho, Luciana; Prufer De Queiroz Campos Araujo, Alexandra; De Mello, Wallace; Gonçalves Ribeiro, Márcia; Cunha, Maria; Cabello, Pedro; Riederer, Ingo; Negroni, Elisa; Desguerre, Isabelle; Veras, Mariana; Yada, Erica; Allenbach, Yves; Benveniste, Olivier; Voit,...
Journal:
Skeletal muscle
Issue:
Volume 5:Issue 1(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Issue 9979 (2nd May 2015)

Authors:
Buyse, Gunnar M; Voit, Thomas; Schara, Ulrike; Straathof, Chiara S M; D'Angelo, M Grazia; Bernert, Günther; Cuisset, Jean-Marie; Finkel, Richard S; Goemans, Nathalie; McDonald, Craig M; Rummey, Christian; Meier, Thomas
Journal:
Lancet
Issue:
Volume 385:Issue 9979(2015)
Page Start:
1748
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy. (27th July 2015)

Authors:
Wary, Claire; Azzabou, Noura; Giraudeau, Céline; Le Louër, Julien; Montus, Marie; Voit, Thomas; Servais, Laurent; Carlier, Pierre
Journal:
NMR in biomedicine
Issue:
Volume 28:Number 9(2015:Sep.)
Page Start:
1150
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗